TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Non-Interventional Open Label Prospective Observational Comparative Study On Evaluation Of Compliance Of The Empiric Treatment With Azithromycin SR Versus Amoxiclav 1000 Mg In Adult Patients With Mild To Moderate Community Acquired Pneumonia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Males or not pregnant or lactating females, 18 years of age or older, for whom oral antibacterial therapy is indicated with clinically evidence of Diagnosis of pneumonia, based on usual clinical practice:~  1. Physical examination and auscultatory findings (dullness on percussion, bronchial breath sounds, egophony, dry or fine most rales).~ 2. Body temperature \>38 degrees C.~Exclusion Criteria:~* Known or suspected hypersensitivity or intolerance or contraindications to Azithromycin.~* Amoxiclav according to LPDs, pregnant or lactating women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Z-max treated group (Type: None): Patients with Community-Acquired Pneumonia
- Amoxiclav treated group (Type: None): Patients with Community-Acquired Pneumonia

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Postop Catheterization for Urinary Retention

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* All female patients who undergo urogynecological surgery procedures at NorthShore University HealthSystem and consent to participate~Exclusion Criteria:~* Patients who cannot read, comprehend, and write in English

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Energy Balance Following Islet Transplantation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Islet transplant and pump therapy~  * Male or Female~ * Age 18 or over~ * Type 1 diabetes.~ * On waiting list for islet transplantation or insulin pump therapy.~ * Normal renal function (GFR \>60).~ * Normal thyroid function (those on thyroxine may be included provided their thyroid function tests are normal).~ * Able to understand and undertake the study procedures.~ * Able to give signed informed consent.~* Healthy controls~  * Male or Female.~ * Age 18 or over.~ * Glucose tolerant.~ * Normal renal function (GFR \>60).~ * Normal thyroid function (those on thyroxine may be included provided their thyroid function tests are normal).~ * Willingness to understand and undertake study procedures.~ * Able to give signed informed consent.~Exclusion Criteria:~* Islet transplant and pump therapy~  * Age less than 18~ * Impaired renal function (GFR \<60)~ * Impaired thyroid function despite therapy~ * Unable to adhere to the study timetable.~ * Unwilling to give informed consent.~* Healthy Controls~  * Age less than 18~ * Impaired glucose-tolerance~ * Impaired thyroid function~ * Impaired renal function (GFR \<60)~ * Unable to adhere to the study timetable.~ * Unwilling to give informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Islet Transplant Patients (Type: ACTIVE_COMPARATOR): Patients with Type 1 Diabetes who are on the waiting list to undergo an islet transplant.
- Insulin Pump Therapy Patients (Type: ACTIVE_COMPARATOR): Patients with Type 1 Diabetes waiting to start on an Insulin Pump.
- Healthy Volunteers (Type: OTHER): Participants with no Diabetes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Correlation of FeNO, Blood Eosinophils, Bronchoalveolar Lavage Findings and Bronchial Epithelium Histopathology in Patients With Chronic Obstructive Pulmonary Disease and Asthma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with diagnosis of COPD or asthma (according to the guidelines)~* Age \>18 years~* Indication for bronchoscopy for medical reasons (not study-related)~* Ability to provide informed consent~Exclusion Criteria:~* paO2 \<60 mmHg on 4L 02 /min, paCO2 \> 55 mmHg on room air~* FEV1 \<20%~* Pulmonary infection or exacerbation within the last 4 weeks~* Additional pulmonary diseases (pneumonia, lung cancer, tuberculosis, interstitial lung disease)~* Contraindication for BAL, PSB sampling or endobronchial biopsy~* Current use of anticoagulants that can not be stopped for bronchoscopy~* Heart failure with left ventricular ejection fraction \<30%~* Myocardial infarction in previous 6 months~* Significant pulmonary hypertension (PAPS \>45 mmHg, right heart failure \[echocardiography\] and/or PAPm \>35 mmHg \[right heart catheter\])

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with COPD (Type: None): The following parameters are to be evaluated:~* Blood eosinophils~* FeNO~* Eosinophils in bronchoalveolar lavage~* Tissue eosinophilia (protected specimen brush sampling, endobronchial biopsy)
- Patients with asthma (Type: None): The following parameters are to be evaluated:~* Blood eosinophils~* FeNO~* Eosinophils in bronchoalveolar lavage~* Tissue eosinophilia (protected specimen brush sampling, endobronchial biopsy)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Neuropathic in the Acute Post Operative Phase

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* age \> 18 years old~Exclusion Criteria:~* do not under stand Danish~* cognitive reduction~* previous thoracic surgery~* Pregnant or nursing~* inability to cooperate to pain scoring

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- lung cancer surgery (Type: None): Patients undergoing thoracotomy for lung cancer

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: PERT for Treatment of Exocrine Pancreatic Insufficiency in Patients With Unresectable Pancreatic Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients 18-80 years~* Underlying pancreatic adenocarcinoma, unresectable (local invasion or distant metastasis)~* On established chemotherapy regimen for pancreas cancer, which will be continued over the time of study~* Fecal elastase-1 test (FE1) less than 200 mcg pancreatic elastase/g stool~Exclusion Criteria:~* Common bile duct obstruction resulting in obstructive jaundice~* Celiac disease~* Crohn's disease~* Benign pancreatic conditions~* Bowel obstruction~* Surgically altered bowel anatomy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo First, then Pancrelipase (Type: EXPERIMENTAL): Placebo oral capsule: 3 capsules taken with or after meals, and 2 capsules taken with or after snacks during 4 weeks in first intervention period, and Pancrelipase 3 capsules are taken with or after meals (4800 lipase units) and 2 capsules with or after snacks (3200 lipase units) during 4 weeks in second intervention period (after 2 week washout period).
- Pancrelipase First, then Placebo (Type: EXPERIMENTAL): Pancrelipase 3 capsules are taken with or after meals (4800 lipase units) and 2 capsules with or after snacks (3200 lipase units) during 4 weeks in first intervention period, and Placebo oral capsule: 3 capsules taken with or after meals, and 2 capsules taken with or after snacks during 4 weeks in second intervention period (after 2 week washout period).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Rasburicase for the Treatment/Prevention of Hyperuricemia in Adult Patients With Relapsing Aggressive Non Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Patients with histologically proven aggressive Non Hodgkin's Lymphoma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Live, Attenuated Influenza Vaccination in Preterm and Full-Term Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Subjects must meet all relevant criteria (by time of influenza vaccination) to participate.~1. (a) Former premature (\<32 weeks' gestation at birth), VLBW (\<1500 grams' birth weight) infant, 24 months, 0 days - 35 months, 31 days of age, OR (b) Former full-term (37-42 weeks' gestation at birth), normal birth weight (\>2500 grams' birth weight) infant, 24 months, 0 days - 35 months, 31 days of age.~2. Influenza immunization in prior season.~3. Eligible for either influenza immunization (TIV or LAIV).~4. Parental permission.~5. Parents likely to be able to comply with study visits.~Exclusion Criteria:~Subjects may not participate if they meet any one of these criteria.~1. Known immunodeficiency in child or in a close household contact.~2. History of:~   * Recurrent episodes of wheezing,~  * Medically-attended wheezing illness in past year, or~  * Hospitalization for a wheezing illness.~3. Systemic corticosteroid administration at time of influenza vaccination.~4. Requiring supplemental oxygen at time of influenza vaccination.~5. Contraindication to either influenza immunization (e.g. egg allergy, aspirin therapy).~6. Physician-diagnosed influenza illness in the current influenza season.~7. Any condition determined by investigator as likely to interfere with evaluation of the vaccine or be a significant potential health risk to the subject.

- Gender: ALL
- Minimum Age: 24 Months
- Maximum Age: 35 Months
- Healthy Volunteers: t

Study Arms:
- Live attenuated influenza vaccine (Type: EXPERIMENTAL): One dose of live attenuated influenza vaccine, according to routine immunization recommendations
- Inactivated influenza vaccine (Type: ACTIVE_COMPARATOR): One dose of inactivated influenza vaccine, according to routine immunization recommendations

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Virtual Reality on Pulmonary Recovery and Mobility in Patients With Blunt Chest Trauma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Admitted to the trauma ward with sustained blunt chest trauma~* Age≥16~* Patient is willing and able to comply with the study protocol~Exclusion Criteria:~* Neurotrauma with GCS ≤13~* History of dementia, seizures, epilepsy~* Severe hearing/visual impairment not corrected~* Head wounds or damaged skin with which comfortable and hygienic use is not possible.~* Stay at intensive care unit (ICU) during current hospital admission.~* Erect position in bed not possible/allowed.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): The control group will receive usual care. Patients will be instructed to perform respiratory exercises 8 times daily for 10 minutes and to extend these exercises 2 times daily with (sitting) physical exercises for an additional 10 minutes. Respiratory exercises include using incentive spirometry and exercises for deep breathing, huffing and coughing. Patients receive a leaflet with the exercises described and the exercises will be performed once daily under supervision of a physiotherapist. The other sessions will be unsupervised.
- Virtual Reality (Type: EXPERIMENTAL): The intervention group will be instructed to perform the respiratory exercises using the VR-intervention 8 times daily for 10 minutes and to extend these exercises 2 times daily with (sitting) physical exercises for an additional 10 minutes. The respiratory exercises in VR are comparable to the exercises in usual care but performed in a virtual environment and without incentive spirometry. The physical exercises consist of several games through which patients are challenged to reach out to objects while engaging their core. Patients are allowed to continue these exercises or play some relaxation games for up to 30 minutes per session in total. The exercises will be performed once daily under supervision of a physiotherapist. The other sessions will be unsupervised.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Optimizing Management of the 2nd Stage of Labor: Multicenter Randomized Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Singleton term pregnancy: gestational age ≥37 weeks~2. Nulliparous women~3. Neuraxial anesthesia: epidural or combined epidural-spinal anesthesia~Exclusion Criteria:~1. Preterm: gestational age \<37 weeks (preterm infants have an a priori risk for adverse outcomes, which is driven more by gestational age than the timing of maternal pushing in the second stage)~2. Multiple gestation (incidence of multiple gestation is small and there are unique delivery considerations)~3. Multiparous women~4. Non-reassuring fetal heart rate tracing (will be an indication for expedited delivery)~5. Contraindication to vaginal delivery including: non-vertex presentation, placenta previa, prior classical cesarean, etc.~6. No neuraxial anesthesia: epidural or combined epidural-spinal anesthesia (subjects without adequate pain control tend to push involuntarily and cannot delay pushing)~7. Pregnancy complications requiring expedited delivery: severe preeclampsia, placental abruption, maternal cardiac disease~8. Fetal head visible at the introitus at complete cervical dilation

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Delayed pushing (Type: ACTIVE_COMPARATOR): None
- Immediate pushing (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Anti PD-L1 Antibody + Anti CTLA-4 Antibody in Combination With Hormone Therapy in Patients With Hormone Receptor Positive HER2-negative Recurrent or Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients aged \>= 20 years at informed consent.~2. Patients who have provided written informed consent themselves.~3. Patients who have metastatic and/or advanced lesion~4. Documentation of ER-positive and/or PR-positive tumor (\>=1% positive stained cells).~5. Patients with cancer confirmed to be HER2-negative.~6. Patients with confirmed menopause~7. Patients who have plans of 2nd hormone therapy.~8. Patients with a measurable lesion based on RECIST 1.1~9. Patients with ECOG PS of 0 to 1.~10. Patients without any severe disorder in the major organs.~Exclusion Criteria:~-~Exclusion Criteria:~1. Active or prior documented autoimmune disease within the past 2 years.~2. Current or prior use of immunosuppressive medication within 28 days before the first dose of durvalumab or tremelimumab~3. Patients with central nervous system metastasis~4. Patients with life-threatening disease.~5. Patients with a history of treatment with anti-PD-1, anti-PD-L1, anti-PD-L2 or anti-CTLA-4 antibody drug.~6. Patients who have received live vaccination within 30 days before start of the investigational products.~7. Patients with a past medical history of pneumonia requiring steroid treatment or with a past medical history of interstitial pneumonia.~8. Patients considered ineligible for participation in this study by their attending physicians.

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Durvalmab&Tremelimumab&Fulvestrant (Type: EXPERIMENTAL): Durvalmab\&Tremelimumab\&Fulvestrant

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Sildenafil (Viagra) for the Treatment of Dyskinesias in Parkinson's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of idiopathic Parkinson's disease, Hoehn and Yahr stage 2.0 to 4.0.~2. Presence of drug-induced dyskinesias~3. Age\>40 years.~4. Willingness and ability to comply with the study requirements and give informed consent.~Exclusion Criteria:~1. Atypical parkinsonian syndrome due to drugs, metabolic disorders, encephalitis, or degenerative diseases.~2. History of stereotaxic brain surgery.~3. Clinical history of dementia.~4. Known major psychiatric disorder, major depression, schizophrenia. Known alcoholism or substance dependence within previous 12 months.~5. History of major hematological, renal, or hepatic abnormalities.~6. Known coronary artery disease including angina or myocardial infarction within the last 6 months. Significant cardiovascular disease including cardiac failure, unstable angina or life-threatening arrhythmia within the last 6 months.~7. History of stroke within the last 6 months.~8. Abnormal EKG consistent with cardiac ischemia.~9. Treatment with nitrates. Nitrates or any NO donors in any dosage form (oral, sublingual, transdermal, inhalation, or aerosols).~10. Malignant hypertension or SBP . 180 or \<90, or DBP .110 or \<50.~11. History of priapism.~12. Known history of retinitis pigmentosa.~13. Positive pregnancy test.~14. History of bleeding disorder.~15. Patients with active peptic ulcer disease associated with bleeding.~16. Unwillingness to use adequate contraceptive methods if of childbearing potential.~17. Patients with medical or psychological condition or social circumstances that would impair their ability to participate in the study.~18. Use of Viagra or any experimental drugs within 30 days of screening visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Viagra (Type: EXPERIMENTAL): subjects will be randomized to active treatment for 2 weeks, washout for 1 week, then enter the other study arm for two weeks.
- Placebo comparator (Type: PLACEBO_COMPARATOR): subjects will be randomized to placebo treatment for 2 weeks, washout for 1 week, then enter the other study arm for two weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Psychology of Minimally Invasive Surgical Scars

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Body Mass Index 35 to 45~* Undergoing Bariatric Surgery~Exclusion Criteria:~* Body Mass Index \<35 or \>45~* Previous Bariatric Surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard Laparoscopic Approach (Type: ACTIVE_COMPARATOR): Minimally invasive laparoscopic procedure with 5-10 mm incisions.
- Percutaneous Approach (Type: ACTIVE_COMPARATOR): Minimally invasive laparoscopic procedure with 2-3 mm incisions.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues